Rigel Pharmaceuticals Statistics
Share Statistics
Rigel Pharmaceuticals has 17.61M shares outstanding. The number of shares has increased by -89.91% in one year.
| Shares Outstanding | 17.61M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.21% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 17.27M |
| Failed to Deliver (FTD) Shares | 1.96K |
| FTD / Avg. Volume | 0.88% |
Short Selling Information
The latest short interest is 661.19K, so 3.75% of the outstanding shares have been sold short.
| Short Interest | 661.19K |
| Short % of Shares Out | 3.75% |
| Short % of Float | 3.83% |
| Short Ratio (days to cover) | 3.91 |
Valuation Ratios
The PE ratio is -10.06 and the forward PE ratio is 30.93.
| PE Ratio | -10.06 |
| Forward PE | 30.93 |
| PS Ratio | 2.16 |
| Forward PS | 1.7 |
| PB Ratio | -8.81 |
| P/FCF Ratio | -12.16 |
| PEG Ratio | n/a |
Enterprise Valuation
Rigel Pharmaceuticals Inc. has an Enterprise Value (EV) of 280.12M.
| EV / Earnings | -11.16 |
| EV / Sales | 2.4 |
| EV / EBITDA | -16.5 |
| EV / EBIT | -13.67 |
| EV / FCF | -13.5 |
Financial Position
The company has a current ratio of 1.86, with a Debt / Equity ratio of -2.1.
| Current Ratio | 1.86 |
| Quick Ratio | 1.76 |
| Debt / Equity | -2.1 |
| Total Debt / Capitalization | 190.5 |
| Cash Flow / Debt | -0.1 |
| Interest Coverage | -2.98 |
Financial Efficiency
Return on equity (ROE) is 0.88% and return on capital (ROIC) is -64.16%.
| Return on Equity (ROE) | 0.88% |
| Return on Assets (ROA) | -0.21% |
| Return on Capital (ROIC) | -64.16% |
| Revenue Per Employee | 795.12K |
| Profits Per Employee | -170.69K |
| Employee Count | 147 |
| Asset Turnover | 1 |
| Inventory Turnover | 1.29 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 46.12% in the last 52 weeks. The beta is 0.95, so Rigel Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 0.95 |
| 52-Week Price Change | 46.12% |
| 50-Day Moving Average | 19.78 |
| 200-Day Moving Average | 13.71 |
| Relative Strength Index (RSI) | 35.03 |
| Average Volume (20 Days) | 221.58K |
Income Statement
In the last 12 months, Rigel Pharmaceuticals had revenue of $116.88M and earned -$25.09M in profits. Earnings per share was $-1.44.
| Revenue | 116.88M |
| Gross Profit | 109.77M |
| Operating Income | -20.49M |
| Net Income | -25.09M |
| EBITDA | -16.98M |
| EBIT | -20.49M |
| Earnings Per Share (EPS) | -1.44 |
Balance Sheet
The company has $32.79M in cash and $60.58M in debt, giving a net cash position of -$27.79M.
| Cash & Cash Equivalents | 32.79M |
| Total Debt | 60.58M |
| Net Cash | -27.79M |
| Retained Earnings | -1.41B |
| Total Assets | 139.42M |
| Working Capital | 52.16M |
Cash Flow
In the last 12 months, operating cash flow was -$5.74M and capital expenditures -$15.00M, giving a free cash flow of -$20.74M.
| Operating Cash Flow | -5.74M |
| Capital Expenditures | -15.00M |
| Free Cash Flow | -20.74M |
| FCF Per Share | -1.19 |
Margins
Gross margin is 93.92%, with operating and profit margins of -17.53% and -21.47%.
| Gross Margin | 93.92% |
| Operating Margin | -17.53% |
| Pretax Margin | -21.47% |
| Profit Margin | -21.47% |
| EBITDA Margin | -14.53% |
| EBIT Margin | -17.53% |
| FCF Margin | -17.75% |
Dividends & Yields
RIGL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -7.64% |
| FCF Yield | -6.25% |
Analyst Forecast
The average price target for RIGL is $25, which is 32.6% higher than the current price. The consensus rating is "Hold".
| Price Target | $25 |
| Price Target Difference | 32.6% |
| Analyst Consensus | Hold |
| Analyst Count | 5 |
Stock Splits
The last stock split was on Jun 27, 2024. It was a backward split with a ratio of 1:10.
| Last Split Date | Jun 27, 2024 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -10.95 |
| Piotroski F-Score | 5 |